Gene therapy for brain tumors: Basic developments and clinical implementation

[1]  L. Levine,et al.  Differentiated Rat Glial Cell Strain in Tissue Culture , 1968, Science.

[2]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[3]  W. Sweet,et al.  Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. , 1971, Journal of neurosurgery.

[4]  J. Folkman,et al.  SELF-REGULATION OF GROWTH IN THREE DIMENSIONS , 1973, The Journal of experimental medicine.

[5]  E. Borden,et al.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.

[6]  R. Puri,et al.  Novel anti–brain tumor cytotoxins specific for cancer cells , 1998, Nature Biotechnology.

[7]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[8]  F. Graham,et al.  Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. , 1999, Human gene therapy.

[9]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[10]  Bing Chen,et al.  Evaluation of combined vaccinia virus–mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model , 2000, Cancer Gene Therapy.

[11]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[12]  V. Heidecke,et al.  Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme , 2000, Gene Therapy.

[13]  W. Cavenee,et al.  Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. , 2001, Cancer Letters.

[14]  K. Black,et al.  Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer , 2002, Cancer Gene Therapy.

[15]  L. Parada,et al.  The Molecular and Genetic Basis of Neurological Tumours , 2002, Nature Reviews Cancer.

[16]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Avezaat,et al.  Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  D. Largaespada,et al.  Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  P. Kleihues,et al.  Morphology of malignant gliomas induced in rabbits by systemic application of N-Methyl-N-nitrosourea , 2004, Zeitschrift für Neurologie.

[20]  I. Germano,et al.  Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[21]  K. Hoang-Xuan,et al.  Molecular changes in gliomas , 2004, Current opinion in oncology.

[22]  M. Rosenblum,et al.  Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis , 2004, Cancer Research.

[23]  C. Barcia,et al.  Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  A. Mintz,et al.  Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. , 2004, Neoplasia.

[25]  S. Ylä-Herttuala,et al.  AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  C. James,et al.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.

[27]  K. Lamborn,et al.  Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model , 2005, Cancer Gene Therapy.

[28]  S. Kyo,et al.  Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. , 2005, Human gene therapy.

[29]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[30]  A. Ribas,et al.  Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. , 2005, Cancer research.

[31]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[32]  P. Morel,et al.  Polarization of naive T cells into Th1 or Th2 by distinct cytokine‐driven murine dendritic cell populations: implications for immunotherapy , 2005, Journal of leukocyte biology.

[33]  M. Assanah,et al.  Glial Progenitors in Adult White Matter Are Driven to Form Malignant Gliomas by Platelet-Derived Growth Factor-Expressing Retroviruses , 2006, The Journal of Neuroscience.

[34]  Margaret Wrensch,et al.  Epidemiology and molecular pathology of glioma , 2006, Nature Clinical Practice Neurology.

[35]  J. Tonn.  Neuro-Oncology of CNS Tumors , 2006 .

[36]  K. Leong,et al.  Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors , 2007, Cancer Gene Therapy.

[37]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[38]  Gabriele Schackert,et al.  Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[39]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[40]  Pierre-Marie Martin,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[42]  R. Lonser,et al.  Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. , 2007, Cancer research.

[43]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Jonathan Lerner,et al.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression , 2007, Journal of Neuro-Oncology.

[45]  S. Rosenfeld,et al.  A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  I. Pollack,et al.  Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas , 2008, Journal of Neuro-Oncology.

[47]  W. Debinski,et al.  Interleukin-13 Receptor α2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy , 2008, Clinical Cancer Research.

[48]  P. Lowenstein,et al.  Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  H. A. Schreiber,et al.  Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulation. , 2008, Current opinion in pharmacology.

[50]  S. Sathornsumetee,et al.  Designer Therapies for Glioblastoma Multiforme , 2008, Annals of the New York Academy of Sciences.

[51]  J. Sarkaria,et al.  Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[53]  S. Hassenbusch,et al.  Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. , 2008, Neuro-oncology.

[54]  H. Wajant.  The role of TNF in cancer. , 2009, Results and problems in cell differentiation.

[55]  P. Lowenstein,et al.  Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? , 2009, Current gene therapy.

[56]  Rolf F. Barth,et al.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas , 2009, Journal of Neuro-Oncology.

[57]  Katsuaki Sato,et al.  Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity , 2009, Clinical Cancer Research.

[58]  Benjamin Purow,et al.  Advances in the genetics of glioblastoma: are we reaching critical mass? , 2009, Nature Reviews Neurology.

[59]  Miriam Scadeng,et al.  Development of a novel mouse glioma model using lentiviral vectors , 2009, Nature Medicine.

[60]  D. Largaespada,et al.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA. , 2009, Cancer research.

[61]  A. Ribas,et al.  HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression , 2009, PLoS medicine.

[62]  C. Mamalaki,et al.  T cells as sources and targets of TNF: implications for immunity and autoimmunity. , 2010, Current directions in autoimmunity.

[63]  Steven Piantadosi,et al.  Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States , 2010, Clinical Cancer Research.

[64]  T. Seyfried,et al.  A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion , 2010, Journal of Neuro-Oncology.

[65]  S. Mocellin,et al.  The dual role of tumor necrosis factor (TNF) in cancer biology. , 2010, Current Medicinal Chemistry.

[66]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[67]  L. Chin,et al.  Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. , 2010, Genes & development.

[68]  C. Svendsen,et al.  Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics , 2010, Proceedings of the National Academy of Sciences.

[69]  S. Bhide,et al.  Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck , 2010, Clinical Cancer Research.

[70]  M S Brown,et al.  Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab , 2011, Neurology.

[71]  S. Baker,et al.  Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. , 2011, Journal of pharmaceutical sciences.

[72]  P. Lowenstein,et al.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. , 2011, Neoplasia.

[73]  J. Sarkaria,et al.  Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery , 2011, Current protocols in pharmacology.

[74]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[75]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Hideo Nakamura,et al.  NKX2.2 suppresses self-renewal of glioma-initiating cells. , 2011, Cancer research.

[77]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.